This observational study is looking at how a treatment called Nivolumab affects atypical (unusual) moles, also known as dysplastic nevi, in people who have had melanoma. Nivolumab is an immunotherapy drug that targets a protein called PD-1 on immune cells, helping your body fight cancer. Researchers want to see if Nivolumab can help prevent melanoma by changing these atypical moles. They will measure changes in the moles' color and appearance for up to 12 months. You could be eligible if you are at least 18 years old, have a history of melanoma (Stages IIB, IIC, IIIA, IIIB, or IIIC), and have at least two atypical moles that are 4mm or larger. The study aims to enroll 30 participants.

Study design

This is an observational study involving 30 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes for up to 12 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.